Mitomycin C for the treatment of bladder cancer

Minerva Urologica e Nefrologica

Volumn 62, Issue 2, 2010, Pages 133-144

  Volpe, A ^a   Racioppi, M ^a   D'Agostino, D ^a   Cappa, E ^a   Filianoti, A ^a   Bassi, P F ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Mitomycin; Therapeutics; Urinary bladder neoplasms

Indexed keywords

BCG VACCINE; BICARBONATE; CORTICOSTEROID; MITOMYCIN C;

BACTERIAL CYSTITIS; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURGERY; CARCINOMA IN SITU; CHEMICAL CYSTITIS; CONTACT DERMATITIS; CORTICOSTEROID THERAPY; DELAYED HYPERSENSITIVITY; DERMATITIS; DESQUAMATION; DISEASE FREE INTERVAL; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; FEVER; FLU LIKE SYNDROME; HEMATURIA; HUMAN; HYPERTHERMIA; MALAISE; NONHUMAN; PATCH TEST; POSTOPERATIVE CARE; RASH; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TRANSURETHRAL RESECTION; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, INTRAVESICAL; ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS AS TOPIC; DRUG ERUPTIONS; HUMANS; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 77957704932     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Jemal A. Cancer Statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Devesa SS, Blot WJ, Stone BJ, , Miller BA, Tarone RE, Fraumeni JF Jr. Recent cancer trends in the United States. J Natl Cancer Inst 1995;87:175-82.
3. Basi scientifiche per la definizione di linee-guida in ambito clinico per i Tumori della Vescica. Progetto Strategico Oncologia. Consiglio Nazionale delle Ricerche e Ministero dell'Istruzione, dell'Università e della Ricerca, 2005.
4. Kirkali Z, Chan T, Manoharan M, Algaba F, Bush C, Cheng L et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(suppl. 6A):4.
5. Pashos CL, Bottleman MF, Laskin BL, Radaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 2002;10:311.
6. Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. The economic consequences of prostate and bladder cancer in the UK. BJU International 2004;95:59.
7. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828.
8. Herr, WH, "NaTURBal History of Non muscle invasive Bladder Tumors: 10-20 Years Follow-up of Treated Patients". World J Urol 1997;15:84-8.
9. Brake M, Leortzer H, Horsch R, Keller H. Long term results of intravesical BCG therapy for stage T1 non muscle invasive bladder cancer. Urology 2000;55:673-7.
10. Herr HW, Laudone VP, Whitmore WF Jr. An overview of intravesical therapy for non muscle invasive bladder tumors. J Urol 1987;138:1363-8.
11. Rubben H, Lutzyer W, Fisher N, Deutz F, Lagrange W, Giani G. naTURBal history and treatment of low and high risk non muscle invasive bladder tumors. J Urol 1988;13:283-5.
12. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB et al. A randomized trial of intravesical doxorubicin and immunotherapy with bcg for transitional cell carcinoma of the bladder. New Eng J Med 1991;325:1205-9.
13. Pawinski A, Sylverster R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage Ta T1 bladder cancer. J Urol 1996;156:1934-41.
14. Lamm DL, Blumenstein B, Sarosdy MF. Significant long term patients benefit with bcg maintenance therapy: a southwest oncology group study. J Urol 1997;157:831.
15. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA et al. "Maintenance BCG immunotherapy for recurrent Ta, T1 and tis transitional cell carcinoma of the bladder: a randomized SWOG group study. J Urol 2000;163:1124-9.
16. Soloway MS. Managing non muscle invasive bladder cancer: An overview. Urology 1992;40:5-10.
17. Rodrigez FM, Toniolo GC, Bayarri JS. Primary non muscle invasive bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164:680-4.
18. Vögeli TA. The management of non muscle invasive transitional cell carcinoma of the bladder: a critical assessment of contemporary concepts and fuTURBe perspectives. BJU International 2005;96:1171-6.
19. Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B, Sylvester R. A prospective European organization for research and treatment of cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of Epirubicin or water in single Ta, T1 papillary carcinoma of the bladder. J Urol 1993;149:749-52.
20. Kamat AH, Lamm DL. Intravesical therapy for bladder cancer. Urology 2000;55:161-8.
21. Witjes JA, Mungan NA, Debruyne NJ. Management of non muscle invasive bladder cancer with intravesical chemotherapy: An update. Urology 2000;56:19-21.
22. Akaza H, Isaka S. Koiso K, Kotake T. Machida T, Manu A. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of non muscle invasive bladder cancer: prospective, randomised, controlled studies of the Japanese Urological Cancer Research Group. Cancer Chemother Pharmacol 1987;20(suppl):91-6.
23. Kurth K, Tunn U, Ay R, Schroeder FH, Pavone-Macaluso M, Debruyne F. Adjuvant chemotherapy for non muscle invasive transitional cell carcinoma: long-term results of a European organisation for Research and Treatment of Cancer. Randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 1997;158:378-84.
24. Malmström PU, Wijstrom H, Lundholm C, Wester K, Bush C, Norlen BJ. 5-year follow-up of a randomized prospective study comparing MMC and BCG in patients with non muscle invasive bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999;161:1124-7.
25. Krege S, Giani G, Meyer R, Otto T, Rubben H. A randomized multicentric trial of adjuvant therapy in non muscle invasive bladder cancer: transurethral resection only versus transurethral resection plus mitomicyn C versus transurethral resection plus bacillus Calmette-Guerin. Partecipating clinics. J Urol 1996;156:962-6.
26. Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J et al. The effect of intravesical MMC on recurrence of newly diagnosed non muscle invasive bladder cancer: a further report with 7 years of follow up. J Urol 1996;155:1233-8.
27. Malmström P.-U. Intravesical therapy of non muscle invasive bladder cancer. Crit Rev Ocol Hematol 2003;47:109-26.
28. Badalament RA, Farah RN. Treatment of non muscle invasive bladder cancer with intravesical chemotherapy. Semin Surg Oncol 1997;13:335-41.
29. De Bruijn EA, Sleeboom HP, van Helsdingen PJ, van Oosterom AT, Tjaden UR, Maes RA. Pharmacodynamics and pharmacokinetics of intravesical MMC upon different dwelling times. Int J Cancer 1992;51:359-64.
30. Mishina I, Oda K, Murata S. Mitomycin C bladder instillation therapy for bladder tumours. J Urol 1975;11.4:277-19.
31. De Furia M, Bracken B, Johnson DE, Soloway MS, Merrin CE, Morgan LR et al. Phase I-II study of Mitomycin C topical therapy for lowgrade, low stage transitional cell carcinoma of the bladder: an interim report. Cancer Treat RqP 1980;64:225-30.
32. Bracken RB, Swanson DA, Johnson DE, De Furia D, von Eschenbach AC, Crooke S. Role of intravesical Mitomycin C in management of superficial bladder tumours. Llrologt 1980;16:11-5.
33. Harrison GSM, Green DF, Newling D\XIW. et al. A phase II study of intravesical Mitomycin C in thetreatment of superficial bladder cancer. Br J Llrol 7983;55:676-9.
34. Van der Meijden APM, Hall RR, Pavone-Macaluso M et al. Marker tumour response to the sequential combination of intravesical therapy with mitomycin C and BCG-RIVM in multiple superificial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897). Eur Urol 7996;29:199-203.
35. Fluchter
36. Issel
37. Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M et al. Intravesical adjuvant chemotherapy for non muscle invasive transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with MMC and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J Urol 1995;153:934-41.
38. Jauhainen
39. Cant
40. Van der Meijden APM, Hall RR, Pavone-Macaluso M et al. Marker tumour response to the sequential combination of intravesical therapy with mitomycin C and BCG-RIVM in multiple superificial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897). Eur Urol 7996;29:199-203.
41. Lamm DL, Van der Meijden APM, Akaza H et al. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are the limitations and uses? Int J Urol 7995;2(.Suppl2):s23.
42. Soloway MS, Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer 1980;46:1158-63.
43. Fazlioglu A, Tandogdu Z, Kurtulus FO, Parlakkilic O, Cek M. Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant! Urol Int 2009;83:362-3.
44. Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
45. Racioppi M, Porreca A, Foschi N, Delicato G, Destito A, D'Addessi A. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C. Urol Int 2005;75:373-5.
46. Sylvester R, Oosterlinck W, van der Meijden A. A single postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage TaT1 bladder cancer: a metaanalysis of published results of randomized clinical trials. J Urol 2004;171:2186-90.
47. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314-30.
48. American Urological Association Guidelines on Management of Non-Muscle Invasive Bladder Cancer . AUA 2007 Annual Meeting; Anaheim, California
49. Feifer A, Xie X, Brophy JM, Segal R, Kassouf W. contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system. Urology 2010 Apr 13 [Epub ahead of print].
50. Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical MMC: a prospective, randomized clinical trial. J Urol 2006;175:1641-4.
51. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J et al. EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder. Eur Urol2008;54:303-14.
52. Sylvester R, Oosterlinck W, Van der Meijden A. A single postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage TaT1 bladder cancer: a metanalysis of published results of randomized clinical trials. J Urol 2004;171:2186-90.
53. Mostafid AH, Rajkumar RGN, Stewart AB, Singh R. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. BJU Int 2006;97:509-12.
54. Kaasinen E, Rintala E, Hellström P, Viitanen J, Juusela H, Rajala P et al. FinnBladder Group. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring non muscle invasive bladder carcinoma. Eur Urol 2002;42:167-74.
55. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008;53:709-19.
56. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle invasive bladder carcinoma. Eur Urol 2007;52:1123-30.
57. EAU Guidelines on TaT1 (Non-muscle invasive) bladder cancer[Internet]. Available at: http://www.uroweb.org/fileadmin/user-upload/guidelines/ tat1%20bladder%20cancer.pdf. [cited 2008, Apr 8].
58. Fernandez-Gomez J, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Hernandez R et al. Prognostic factors in patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guèrin. Multivariate analysis of data from four randomized CUETO Trials. Eur Urol 2008;53:992-1002.
59. Ali-El-Dein B, Sarhan O, Nabeeh A, Ghoneim MA. Maintenance intravesical BCG therapy for non muscle invasive bladder tumours: 3 week multiple courses versus monthly doses. J Urol 2007;177:522.
60. Vegt PDJ, Witjes JA, Witjes 'WPJ, Doesburg WH, Debruyne FM, van der Meijden AP. A randomized study of intravesical Mitomycin C, bacillus Calmette-Guérin Tice and bacillus Calmette-Guérin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 1995;L53:929-33.
61. De Groot AC, Van der Meijden APM, Conemans JMH and Maibach HI. Frequency and naTURBe of cutaneous reactions to intravesical instillation of mitomycin for superficial bladder cancer. Urology 1992;31:(Suppl)S40:16-9.
62. Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effects of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with non muscle invasive bladder cancer: results of a randomised, prospective, double-blind, placebo controlled, multicentre study. J Urol 2006;176:935-9.
63. Au JL, Baladament RA, Wientjes MG, Young DC, Warner JA, Venema P et al. International MMC Consortium. Methods to improve efficacy of intravesical MMC: results of a randomised phase III trial. J Natl Cancer Inst 2001;93:597-604.
64. Di Stasi SM, Giannantoni A, Giuriolo A, Valenti M, Zampa G, Storti L et al. Sequential BCG and electromotive MMC versus BCG alone for high-risk non muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol 2006;7:43-51.
65. Colombo R, Da Pazzo LF, Lev A, Freschi M, Gallus G, Rigatti P. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for non muscle invasive bladder cancer. J Urol 1996;155:1227-32.
66. Gofrit ON, Sahpiro A, Pode D, Sidi A, Nativ O, Leib Z et al. Combined local bladder hyperthermia and intraveiscal chemotherapy for the treatment of highgrade non muscle invasive bladder cancer. Urology 2004;63:466-71.
67. van der Heijden AG, Kiemeney LA, Gofrit ON, Nativ O, Sidi A, Leib Z et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk non muscle invasive transitional cell carcinoma of the bladder. Eur Urol 2004;46:65-71.
68. Racioppi M, Volpe A, Cappa E, D'Agostino D, Pinto F, D'Addessi A et al. Intensive intravesical Mitomycin C therapy in non-muscle invasive bladder cancer: a dose intensity approach. Urol Int 2010 May 28 [Epub ahead of print).
69. Popert RJ, Goodall J, Coptcoat MJ, Thompson PM, Parmar MK, Masters JR. Non muscle invasive bladder cancer: the response of a marker tumor to a single intravesical instillation of epirubicin. Br J Urol 1994;75:195-9.
70. Bono AV, Hall RR, Denis L, Lovisolo JA, Sylvester R. Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group. Eur Urol 1996;29:385-90.